Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 5. Annual reported cases of notifiable diseases and rates per 100,000, by sex, excluding U.S. Territories - - United States, 2018
Disease Female Male Sex not stated Total
No. Rate No. Rate No. No.
Anthrax — — 1 0.00 — 1
Arboviral diseases
Chikungunya virus disease 79 0.05 38 0.02 — 117
Eastern equine encephalitis virus disease
Neuroinvasive 3 0.00 3 0.00 — 6
Non-neuroinvasive — — — — — —
Jamestown Canyon virus disease
Neuroinvasive 5 0.00 20 0.01 — 25
Non-neuroinvasive 1 0.00 15 0.01 — 16
La Crosse virus disease
Neuroinvasive 43 0.03 40 0.02 — 83
Non-neuroinvasive — — 3 0.00 — 3
Powassan virus disease
Neuroinvasive 7 0.00 14 0.01 — 21
Non-neuroinvasive — — — — — —
St. Louis encephalitis virus disease
Neuroinvasive 2 0.00 3 0.00 — 5
Non-neuroinvasive 2 0.00 1 0.00 — 3
West Nile virus disease
Neuroinvasive 604 0.36 1,053 0.65 — 1,657
Non-neuroinvasive 405 0.24 584 0.36 — 989
Western equine encephalitis virus disease
Neuroinvasive — — — — — —
Non-neuroinvasive — — — — — —
Babesiosis
Total 765 0.55 1,393 1.04 2 2,160
Confirmed 651 0.47 1,208 0.90 2 1,861
Probable 114 0.08 185 0.14 — 299
Botulism
Total 112 0.07 113 0.07 — 225
Foodborne 11 0.01 6 0.00 — 17
Infant 86 4.58 71 3.61 — 157
Other (wound & unspecified) 15 0.01 36 0.02 — 51
Brucellosis 56 0.03 82 0.05 — 138
Campylobacteriosis 33,351 20.09 36,693 22.77 156 70,200
Chancroid — — 3 0.00 — 3
Chlamydia trachomatis infection 1,145,063 689.64 610,447 378.86 3,158 1,758,668
Cholera 5 0.00 9 0.01 — 14
Coccidioidomycosis * 7,032 10.33 8,552 12.82 27 15,611
Cryptosporidiosis
Total 6,476 3.90 6,038 3.75 19 12,533
Confirmed 4,540 2.73 4,428 2.75 12 8,980
Probable 1,936 1.17 1,610 1.00 7 3,553
Cyclosporiasis 1,924 1.30 1,594 1.11 1 3,519
Dengue virus infections †
Dengue 215 0.13 209 0.13 — 424
Dengue-like illness 19 0.01 22 0.01 — 41
Severe dengue 8 0.00 1 0.00 — 9
Diphtheria 1 0.00 — — — 1
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 1,575 0.98 2,430 1.57 3 4,008
Ehrlichia chaffeensis infection 803 0.50 992 0.64 4 1,799
Ehrlichia ewingii infection 10 0.01 23 0.01 — 33
Undetermined ehrlichiosis/anaplasmosis 127 0.08 156 0.10 — 283
Giardiasis 5,957 4.58 9,540 7.55 51 15,548
Gonorrhea 241,074 145.19 341,401 211.88 930 583,405
Haemophilus influenzae, invasive disease
All ages, all serotypes 2,972 1.79 2,568 1.59 33 5,573
Age <5 years
Serotype b 16 0.17 22 0.22 — 38
Non-b serotype 76 0.79 115 1.13 — 191
Nontypeable 97 1.00 123 1.21 2 222
Unknown serotype 72 0.74 102 1.01 1 175
Hansen's disease 30 0.02 43 0.03 17 90
Hantavirus infection, non-hantavirus pulmonary syndrome 1 0.00 1 0.00 — 2
Hantavirus pulmonary syndrome 10 0.01 8 0.01 — 18
Hemolytic uremic syndrome post-diarrheal 220 0.14 156 0.10 — 376
Hepatitis §
A, acute 4,951 2.98 7,497 4.65 26 12,474
B, acute 1,260 0.76 2,050 1.28 12 3,322
B, perinatal infection 15 0.40 8 0.20 — 23
C, acute 2,058 1.31 2,706 1.77 4 4,768
Confirmed 1,605 1.02 2,012 1.32 4 3,621
Probable 453 0.29 694 0.45 — 1,147
C, perinatal infection 117 0.08 97 0.07 — 214
Human immunodeficiency virus diagnoses 6,286 3.79 26,713 16.58 — 32,999
Influenza-associated pediatric mortality 90 0.25 69 0.18 — 159
Invasive pneumococcal disease 
All ages 9,413 7.59 10,328 8.61 116 19,857
Confirmed 9,291 7.49 10,212 8.52 116 19,619
Probable 122 0.10 116 0.10 — 238
Age <5 years 477 0.36 631 0.49 8 1,116
Confirmed 463 5.97 607 7.48 8 1,078
Probable 14 0.18 24 0.30 — 38
Legionellosis 3,637 2.19 6,289 3.90 7 9,933
Leptospirosis 21 0.02 70 0.05 — 91
Listeriosis 452 0.27 406 0.25 6 864
Lyme disease
Total 14,048 8.50 19,092 11.90 526 33,666
Confirmed 9,708 5.87 13,346 8.32 504 23,558
Probable 4,340 2.63 5,746 3.58 22 10,108
Malaria 659 0.40 1,085 0.67 4 1,748
Measles
Total 182 0.11 193 0.12 — 375
Indigenous 147 0.09 149 0.09 — 296
Imported 35 0.02 44 0.03 — 79
Meningococcal disease
All serogroups 161 0.10 166 0.10 — 327
Serogroups ACWY 46 0.03 54 0.03 — 100
Serogroup B 50 0.03 31 0.02 — 81
Other serogroups 10 0.01 13 0.01 — 23
Unknown serogroup 55 0.03 68 0.04 — 123
Mumps 1,032 0.62 1,477 0.92 6 2,515
Novel Influenza A virus infections 5 0.00 9 0.01 — 14
Paratyphoid fever ** 70 0.04 63 0.04 — 133
Pertussis 8,485 5.11 7,064 4.38 60 15,609
Plague — — 1 0.00 — 1
Poliomyelitis, paralytic — — — — — —
Poliovirus infection, nonparalytic — — — — — —
Psittacosis 9 0.01 13 0.01 — 22
Q fever
Total 46 0.03 168 0.10 1 215
Acute 38 0.02 140 0.09 — 178
Chronic 8 0.00 28 0.02 1 37
Rabies
Human 1 0.00 2 0.00 — 3
Rubella 1 0.00 3 0.00 — 4
Rubella, congenital syndrome — — — — — —
Salmonellosis (excluding paratyphoid fever and typhoid fever) †† 32,510 19.58 28,215 17.51 274 60,999
Severe acute respiratory syndrome-associated coronavirus disease — — — — — —
Shiga toxin-producing Escherichia coli (STEC) 8,793 5.30 7,160 4.44 43 15,996
Shigellosis 6,690 4.03 9,587 5.95 56 16,333
Smallpox — — — — — —
Spotted fever rickettsiosis
Total 1,847 1.12 3,690 2.31 7 5,544
Confirmed 51 0.03 73 0.05 — 124
Probable 1,796 1.09 3,617 2.26 7 5,420
Streptococcal toxic shock syndrome 180 0.17 191 0.19 — 371
Syphilis
Total, all stages §§ 22,118 13.32 91,525 56.80 1,402 115,045
Congenital — — — — 1,306 1,306
Primary and secondary 4,995 3.01 30,034 18.64 34 35,063
Tetanus 11 0.01 12 0.01 — 23
Toxic shock syndrome (other than Streptococcal) 23 0.02 10 0.01 — 33
Trichinellosis 1 0.00 — — — 1
Tuberculosis 3,476 2.09 5,527 3.43 22 9,025
Tularemia 80 0.05 149 0.09 — 229
Typhoid fever 192 0.12 209 0.13 — 401
Vancomycin-intermediate Staphylococcus aureus 36 0.03 49 0.04 — 85
Vancomycin-resistant Staphylococcus aureus — — — — — —
Varicella morbidity 3,785 2.79 4,377 3.32 39 8,201
Varicella mortality U U U U U U
Vibriosis
Total 1,239 0.76 1,717 1.08 8 2,964
Confirmed 639 0.39 1,179 0.74 4 1,822
Probable 600 0.37 538 0.34 4 1,142
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever virus — — — — — —
Ebola virus — — — — — —
Guanarito virus — — — — — —
Junin virus — — — — — —
Lassa virus — — — — — —
Lujo virus — — — — — —
Machupo virus — — — — — —
Marburg virus — — — — — —
Sabia virus — — — — — —
Yellow fever — — — — — —
Zika virus
Zika virus disease, congenital ¶¶ 1 0.05 1 0.05 — 2
Zika virus disease, non-congenital 56 0.03 23 0.01 — 79
Zika virus infection, congenital ¶¶ 4 0.21 4 0.20 — 8
Zika virus infection, non-congenital 230 0.14 15 0.01 — 245
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • U: Unavailable — The data are unavailable.
  • * Reportable in <25 states.
  • † Counts include confirmed and probable dengue cases.
  • § Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm.
  • ¶ Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • ** Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • †† Prior to 2018, cases of paratyphoid fever were included as salmonellosis, but beginning in 2018 they are being published as paratyphoid fever.
  • §§ Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); and unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations).
  • ¶¶ Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01).
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
  2. The list of nationally notifiable infectious diseases and conditions for 2018 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2018" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2017 by CSTE for national surveillance, that were implemented in January 2018, including updated surveillance case definitions for anthrax, shiga toxin-producing Escherichia coli, and syphilis. Perinatal hepatitis c virus infection became a new nationally notifiable condition in 2018. While Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) was added to the list of nationally notifiable diseases in 2018, reporting jurisdictions could not submit data for this condition since Office of Management and Budget Paperwork Reduction Act approval was pending during 2018. Publication criteria for the finalized 2018 data are available at https://wonder.cdc.gov/nndss/documents/2018_NNDSS _Publication_Criteria_07122019_updated_09230219.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Annual tables for 2016 and later years are available on CDC WONDER.
  4. Annual summary reports from 1993-2015 are available as published in the MMWR.
  5. NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left).
  6. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a nationally notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Population estimates for incidence rates are July 1st, 2018 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2018, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2018), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released June 25, 2019 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2018 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on June 26, 2019 at https://www.census.gov/data-tools/demo/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal Hepatitis B infection (age restriction in numerator is ≤24 months, denominator is <24 months)
    • Perinatal Hepatitis C infection (age restriction in numerator is ≤36 months, denominator is <36 months)

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2018 (National Center for Health Statistics Natality 2018, as compiled from data provided by the Vital Statistics Cooperative Program). The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases. Congenital syphilis data are published in Syphilis Statistics in the Sexually Transmitted Diseases (STD) surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) and in the historical archives of the STD surveillance report (https://www.cdc.gov/std/stats/archive.htm). The STD surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) updates congenital syphilis cases and rates over time.

  7. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
Suggested Citation: Acknowledgement:
  • CDC acknowledges the Local, State, and Territorial Health Departments that collected the data from a range of case ascertainment sources (e.g., health-care providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.